Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.
Aim(s): Evaluate the role of 68Ga-PET in diagnosis, staging, re-evaluation and change of treatment in a group of controversial NET patients.
Materials and methods: In the last 6 months we performed a 68Ga-PET in 12 controversial NET. We collected demographic data, tumor grade, location, NET therapy, 6 months-previous CT, MRI and SSTR scintigraphy as well as indication and results of 68Ga-PET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Inmaculada Peiró Martínez
To read results and conclusion, please login ...
Further abstracts you may be interested in